QQ客服 官方微博 反馈留言

	A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
	Liu, Ke-Jun; Guan, Zhong-Zhen; Liang, Ying; Yang, Xu-Qing; Peng, Jin; Huang, He; Shao, Qing-Xiang; Wang, Meng-Zhao; Zhu, Yun-Zhong; Wu, Chang-Ping
	2014
卷号	10期号:4页码:717-724
关键词	dicycloplatin platinum derivative first-line therapy non-small-cell lung cancer (NSCLC) phase II study
ISSN号	1734-1922
DOI	10.5114/aoms.2014.44862
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6684215
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Liu, Ke-Jun,Guan, Zhong-Zhen,Liang, Ying,et al. A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers[J],2014,10(4):717-724.
APA	Liu, Ke-Jun.,Guan, Zhong-Zhen.,Liang, Ying.,Yang, Xu-Qing.,Peng, Jin.,...&Wu, Hai-Ying.(2014).A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers.,10(4),717-724.
MLA	Liu, Ke-Jun,et al."A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers".10.4(2014):717-724.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。